Navigation Links
Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
Date:5/1/2009

EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

www.ntii.com


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
2. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
11. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... Aug. 1, 2014  VanDeMark Chemical Inc., ... manufacturer of phosgene and phosgene derivatives in ... it has acquired Framochem Kft, a leading European-based ... Hungary . The purchase unites ... one of the world,s largest, independent manufacturers of ...
(Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... 19, 2012  The Specialty Photonics Division of OFS ... optical fiber, cable, and assemblies for medical device ... "Optical fibers with polyimide coatings for medical applications" ... will present on Sunday, January 22nd at 12:10 ...
... 19, 2012 RESMED INC. (NYSE: RMD ), announced ... results for the second quarter and six months of fiscal year ... will be issued after 1:00 p.m. Pacific Time and the company ... market trends, and future outlook. Please note only the "outside ...
Cached Medicine Technology:OFS to Present Paper on Optical Fibers with Polyimide Coatings for Medical Applications 2ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results 2
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
(Date:8/1/2014)... As it continues to investigate morcellator ... allegedly experienced the spread of uterine cancers due to ... Liebhard LLP notes the growing reaction to Johnson & ... marketed by its Ethicon, Inc. unit from the market. ... some critics of the company said they were “pleasantly ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
(Date:8/1/2014)... 01, 2014 Market Publishers Ltd ... have been added to its catalogue. , ... Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), ... industry drivers include, among others, increasing ageing population, ... In 2015, the pharma market in India is ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
... Mozes HealthDay Reporter , WEDNESDAY, June 30 (HealthDay ... test and a brain scan may best predict the likelihood ... to develop Alzheimer,s disease. Mild cognitive impairment (MCI), is ... language or another mental function severe enough to be noticeable ...
... By Jenifer Goodwin HealthDay Reporter , ... Parkinson,s disease patients who received fetal cell transplants in ... they can prevent the troublesome side effect. The ... they said. "These findings lend much optimism to ...
... the Stanford University School of Medicine have identified a ... because the existence of such a cell in the ... It may also explain why current immunotherapies are largely ... "These cells lack the traditional melanoma cell surface ...
... Smoking, an established risk factor for colon cancer, may induce ... in the development of colon cancer, according to an online ... National Cancer Institute. Cigarette smoking is a ... that people who currently smoke or smoked in the past ...
... led by a team from the University at Buffalo ... randomized double-blinded study to test the safety and efficacy ... on the symptoms and progression of Multiple Sclerosis (MS). ... venous insufficiency (CCSVI) with MS. , In a series ...
... a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory ... than a drug already available for treating cancer. In a ... the Journal of Leukocyte Biology ( http://www.jleukbio.org ), ... to treat cancers that affect white blood cells, induces cell ...
Cached Medicine News:Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 2Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 3Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 4Health News: Parkinson's Transplant Mystery Solved, Researchers Say 2Health News: Parkinson's Transplant Mystery Solved, Researchers Say 3Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes 2Health News:University at Buffalo launches clinical trial of new multiple sclerosis treatment 2Health News:University at Buffalo launches clinical trial of new multiple sclerosis treatment 3Health News:Cancer drug shows promise for treating a wide range of inflammatory diseases 2
... a two-piece Titanium (Ti-6Al-4V) screw offered in ... variety of lengths. The two pieces are ... packaged. A single instrument set contains all ... both Standard and Mini Kompressor Compression Screws. ...
... Avanta Total Wrist is designed ... in patients suffering from rheumatoid, ... The implant is designed as ... bone resection and aiding in ...
... Within the last decade KMI® revolutionized the ... the Universal Total Wrist System. We're at ... next generation product, the Universal2. Like the ... the way patients live with debilitating arthritis. ...
... NeedlePunch is a simple, effective instrument to grasp ... FiberWire stitch and loop. The grasping function of ... soft tissue and precisely place a stitch up ... the tissue, all in one quick step. The ...
Medicine Products: